Dynamic Technology Lab Private Ltd Buys Shares of 2,123 bluebird bio, Inc. (BLUE)

Dynamic Technology Lab Private Ltd bought a new position in bluebird bio, Inc. (NASDAQ:BLUE) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,123 shares of the biotechnology company’s stock, valued at approximately $292,000.

Several other institutional investors and hedge funds also recently modified their holdings of BLUE. Dimensional Fund Advisors LP boosted its stake in shares of bluebird bio by 24.5% in the first quarter. Dimensional Fund Advisors LP now owns 84,961 shares of the biotechnology company’s stock worth $7,723,000 after buying an additional 16,741 shares during the last quarter. Bank of Montreal Can boosted its stake in shares of bluebird bio by 118.9% in the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock worth $176,000 after buying an additional 911 shares during the last quarter. Aperio Group LLC boosted its stake in shares of bluebird bio by 10.9% in the second quarter. Aperio Group LLC now owns 5,001 shares of the biotechnology company’s stock worth $525,000 after buying an additional 491 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of bluebird bio by 15.0% in the second quarter. Russell Investments Group Ltd. now owns 38,882 shares of the biotechnology company’s stock worth $4,084,000 after buying an additional 5,059 shares during the last quarter. Finally, Strs Ohio boosted its stake in shares of bluebird bio by 25.4% in the second quarter. Strs Ohio now owns 7,400 shares of the biotechnology company’s stock worth $777,000 after buying an additional 1,500 shares during the last quarter.

A number of analysts have recently commented on BLUE shares. Morgan Stanley upped their target price on bluebird bio from $103.00 to $105.00 and gave the stock an “equal weight” rating in a research note on Monday, August 7th. BidaskClub upgraded bluebird bio from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. Jefferies Group reiterated a “buy” rating and set a $88.00 price target on shares of bluebird bio in a research report on Friday, August 11th. Evercore ISI initiated coverage on bluebird bio in a research report on Wednesday, August 16th. They set an “in-line” rating and a $102.00 price target on the stock. Finally, Cowen reiterated an “outperform” rating on shares of bluebird bio in a research report on Thursday, August 31st. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $134.35.

In other news, insider Jeffrey T. Walsh sold 35,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $151.38, for a total value of $5,298,300.00. Following the transaction, the insider now owns 62,305 shares in the company, valued at $9,431,730.90. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Nick Leschly sold 2,127 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $145.17, for a total value of $308,776.59. Following the completion of the transaction, the chief executive officer now owns 257,486 shares in the company, valued at approximately $37,379,242.62. The disclosure for this sale can be found here. In the last 90 days, insiders sold 106,918 shares of company stock worth $15,181,462. Company insiders own 3.90% of the company’s stock.

bluebird bio, Inc. (NASDAQ BLUE) opened at $162.30 on Tuesday. bluebird bio, Inc. has a 1 year low of $60.95 and a 1 year high of $174.65.

bluebird bio (NASDAQ:BLUE) last released its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.68) by ($0.05). The firm had revenue of $7.71 million during the quarter, compared to analysts’ expectations of $8.47 million. bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The business’s revenue was up 397.4% compared to the same quarter last year. During the same quarter last year, the business earned ($2.07) EPS. equities research analysts forecast that bluebird bio, Inc. will post -6.68 EPS for the current fiscal year.

WARNING: “Dynamic Technology Lab Private Ltd Buys Shares of 2,123 bluebird bio, Inc. (BLUE)” was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.com-unik.info/2017/12/05/dynamic-technology-lab-private-ltd-buys-shares-of-2123-bluebird-bio-inc-blue.html.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

What are top analysts saying about bluebird bio Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for bluebird bio Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit